VR Logo

Inventiva S.A. (IVA) download report

Healthcare | Biotechnology & Pharma Research

Inventiva S.A. (IVA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Please wait...

Please wait...

Please wait...

Please wait...

Please wait...

About The Company

Business: Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases.

IPO Date: 10-Jul-2020

Co-Founder, CEO & Chairman: Mr. Frederic Cren

Co-Founder, Chief Scientific Officer, Deputy CEO & Director: Dr. Pierre Broqua Ph.D.

Listing: NASDAQ: IVA

Country: France

Headquarters: Daix,

Website: https://www.inventivapharma.com

Key Facts

Market cap: $289.05 Mln

Revenue (TTM): $0.14 Mln

Earnings (TTM): $-49.64 Mln

Cash: $0.00 Mln

Total Debt: $0.00 Mln

Insider's Holding: 0.00%

Liquidity: Low

52 Week range: $6.29 - 15.78

Shares outstanding: 40,873,600

9 Years Aggregate:

  • CFO: $-217.47 Mln
  • EBITDA: $-212.07 Mln
  • Net Profit: $-194.81 Mln

Stock Performance

Time Period Inventiva S.A. (IVA) S&P BSE Sensex S&P Small-Cap 600
1 month-28.32-2.01-4.75
3 months-40.72-7.32-12.65
1 Year-51.970.45-16.28
3 Years--10.328.01
5 Years--11.296.35
10 Years--12.1410.55
As on 27-Jun-2022
Year Inventiva S.A. (IVA) S&P Small-Cap 600 S&P BSE Sensex